Top of page
Lawyers

Jennifer Ying Lan

Lawyers

Filters

DuPont de Nemours $2 billion notes offering
Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering by DuPont de Nemours, Inc. of $2 billion aggregate principal amount of…
Snap-on $500 million notes offering
Davis Polk advised the representatives of the several underwriters, in connection with an SEC-registered offering by Snap-on Incorporated of $500 million aggregate principal amount of its 3…
Emerson Electric $1.5 billion notes offering
Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by Emerson Electric Co. of $500 million aggregate principal amount of 1.800%…
IDEX $500 million notes offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with an SEC-registered offering by IDEX Corporation of $500 million…
General Dynamics $4 billion notes offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in an SEC-registered offering by General Dynamics Corporation of $750 million aggregate…
Zai Lab $300 million follow-on offering of ADSs
Davis Polk advised Zai Lab Limited in connection with its follow-on offering of approximately $300 million of American depositary shares, representing 5,500,000 ordinary shares by the…
Crocs, Inc. Secondary Offering
Davis Polk advised the underwriter in connection with the secondary offering of 6,864,545 shares of common stock of Crocs, Inc. by selling stockholders affiliated with The Blackstone Group…
Aprea Therapeutics, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with the $97.75 million initial public offering of 6,516,667 shares of common stock of Aprea Therapeutics, Inc., which includes 850,000…
Stoke Therapeutics, Inc. Initial Public Offering
Davis Polk advised the representatives of the underwriters in connection with the $163.3 million initial public offering of 9,074,776 shares of common stock of Stoke Therapeutics, Inc.,…
Back to top